ClinicalTrials.gg
RecruitingNCT07295509Updated Mar 20, 2026

A Study of Picankibart in Patients With Active Psoriatic Arthritis

A Phase 2/3 interventional study of Placebo and Picankibart in Psoriatic Arthritis, sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (part of Innovent Biologics, Inc.) · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 34 studies in Arthritis, Psoriatic with a site in China — 10 open to participants now, 19 under way, 11 of them phase 3. Arthritis, Psoriatic · China.

Planned enrollment
12th of 27
222 · median 208
Started
2025
with 6 others
Phase 2/3
Only one
of the 34
Primary completion
2029-12
later than 15 of 18 live
Registered
29th of 34
by date

Among the 34 studies in Arthritis, Psoriatic with a site in China, this one is the 12th largest by planned enrollment of the 27 interventional ones that give a count, is one of 7 that started in 2025, is the only one in phase 2/3, reaches primary completion later than 15 of the 18 other live ones, and was the 29th registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

10 of the 34 studies in Arthritis, Psoriatic with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 52 (59%) set no upper age limit and 27 (31%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Arthritis, Psoriatic with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II/III clinical trial evaluating the efficacy and safety of picankibart (IBI112) in patients with active psoriatic arthritis (PsA). The study consists of two stages: Phase II dose-finding (n=90) and Phase III confirmatory (n=132). Participants will receive subcutaneous (SC) injections of either picankibart (200mg) or placebo with different dosing schedules, with placebo crossover to active treatment at Week 26. The Phase II portion will identify optimal dosing for Phase III, which will confirm efficacy. The study will evaluate improvements in joint symptoms, physical function, quality of life, and skin manifestations. Primary endpoint is percentage of participants who achieved an American College of Rheumatology (ACR) 20 Response at Week 24.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years
  2. Diagnosed with PsA for ≥3 months, and meeting Classification Criteria for Psoriatic Arthritis (CASPAR) at screening
  3. Having active PsA: ≥3 tender joints and ≥3 swollen joints at screening and baseline
  4. Having active plaque psoriasis (≥1 lesion ≥2cm) or nail psoriasis, or a documented history of plaque psoriasis
  5. Inadequate response or intolerance to prior NSAIDs or non-biologic DMARDs
  6. Stable doses of protocol permitted background therapy (if any)

Exclusion criteria

Exclusion Criteria:

  1. Other inflammatory conditions that may affect the evaluation of the study drug
  2. Prior treatment with >2 biologic agents
  3. Recent use of prohibited medications (specific apply)
  4. Non-plaque psoriasis forms or drug-induced psoriasis
  5. Severe, progressive, or uncontrolled renal, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, hematological, rheumatic (excluding PsA), psychiatric, or genitourinary conditions
  6. Significant laboratory abnormalities
  7. Pregnancy or breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
222 participants (estimated)

Study arms

  • Experimental
    Picankibart Group 2

    Participants receive picankibart SC at each scheduled dosing timepoint with dosing interval 2.

    Other: Placebo · Drug: Picankibart

  • Placebo comparator
    Placebo Group

    Participants receive placebo SC at each scheduled dosing timepoint. Treatment of picankibart starts at Week 26.

    Other: Placebo · Drug: Picankibart

  • Experimental
    Picankibart Group 1

    Participants receive picankibart SC at each scheduled dosing timepoint with dosing interval 1.

    Drug: Picankibart

Interventions

  • OtherPlacebo

    Placebo administered SC at each scheduled dosing timepoint.

  • Picankibart administered SC at each scheduled dosing timepoint.

06

What researchers measure

Primary outcomes

  1. Percentage of participants who achieved an American College of Rheumatology (ACR) 20 response

    The ACR20 response is defined as ≥20% improvement in swollen joint count (66 joints) and tender joint count (68 joints) and ≥20% improvement in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS; 0-100 millimeter \[mm\], 0 mm=no pain and 100 mm=worst possible pain), participant's global assessment of disease activity by using VAS (scale ranges from 0 mm to 100 mm, \[0 mm= very well to 100 mm= very poor\]), physician's global assessment of disease activity using VAS (scale ranges from 0 to 100), \[0 = no arthritis to 100 = extremely active arthritis\], participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and C-reactive protein (CRP).

    Time frame: Week 26

Secondary outcomes

  1. Change from baseline in Disease Activity Score in 28 Joints (DAS28)-CRP score

    The DAS28-CRP is a measure of disease activity based on swollen and tender joint counts in 28 joints, CRP and the participant's global assessment of disease activity. The range of DAS28-CRP score is 0-10. Higher score means more disease activity.

    Time frame: Week 26, and from baseline to Week 56

  2. Percentage of participants who achieved an ACR50 response

    The ACR50 response is defined as ≥50% improvement in swollen joint count (66 joints) and tender joint count (68 joints) and ≥50% improvement in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS; 0-100 millimeter \[mm\], 0 mm=no pain and 100 mm=worst possible pain), participant's global assessment of disease activity by using VAS (scale ranges from 0 mm to 100 mm, \[0 mm= very well to 100 mm= very poor\]), physician's global assessment of disease activity using VAS (scale ranges from 0 to 100), \[0 = no arthritis to 100 = extremely active arthritis\], participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and C-reactive protein (CRP).

    Time frame: Week 26, and from baseline to Week 56

  3. Percentage of participants who achieved an ACR70 response

    The ACR70 response is defined as ≥70% improvement in swollen joint count (66 joints) and tender joint count (68 joints) and ≥70% improvement in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS; 0-100 millimeter \[mm\], 0 mm=no pain and 100 mm=worst possible pain), participant's global assessment of disease activity by using VAS (scale ranges from 0 mm to 100 mm, \[0 mm= very well to 100 mm= very poor\]), physician's global assessment of disease activity using VAS (scale ranges from 0 to 100), \[0 = no arthritis to 100 = extremely active arthritis\], participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and C-reactive protein (CRP).

    Time frame: Week 26, and from baseline to Week 56

  4. Change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)

    HAQ-DI measures improvement in physical function/disability. It is defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area.

    Time frame: Week 26, and from baseline to Week 56

  5. Change from baseline in Short Form Health Survey 36 (SF-36) Physical Component Summary (PCS) score

    The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100) and a positive change from Baseline indicates improvement.

    Time frame: Week 26, and from baseline to Week 56

  6. Enthesitis/dactylitis resolution rates

    Percentage of participants with complete resolution of enthesitis (inflammation at tendon/ligament attachments) or dactylitis (sausage-digit swelling).

    Time frame: Week 26, and from baseline to Week 56

  7. Percentage of participants who achieved 75%Psoriasis Area and Severity Index 75 response

    Percentage of participants who achieve at least 75% or 90% or 100% reduction in Psoriasis Area and Severity Index (PASI) score, assessing skin lesion severity in psoriatic arthritis patients.

    Time frame: From baseline to Week 56

  8. Change from baseline in van der Heijde-modified Total Sharp Score (vdH-mTSS)

    The vdH-mTSS is a measure of change in joint health. X-rays of hands and feet are obtained at screening, Week 26 and Week 56. Totals for hands and feet for erosion scores (range 0 to 320) and joint space narrowing scores (range 0 to 208) were calculated and added to obtain the vdH-mTSS (range = 0 \[normal\] to 528 \[maximal disease\]). An increase in vdH-mTSS from baseline represents disease progression and/or joint worsening.

    Time frame: Week 26 and Week 56

  9. Percentage of participants who experienced adverse events (AEs)

    An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment.

    Time frame: From baseline to Week 56

  10. Percentage of participants who experienced serious adverse events (SAEs)

    An SAE is an AE that results in death, is life-threatening, results in or prolongs hospitalization, results in congenital anomaly, persistent or significant disability/incapacity, spontaneous or elective abortion, or requires intervention to prevent a serious outcome.

    Time frame: From baseline to Week 56

  11. Maximum plasma concentration (Cmax) of picankibart

    Plasma concentration of picankibart is evaluated at each scheduled dosing timepoint. Cmax is the highest concentration of a drug in the blood.

    Time frame: From baseline to Week 56

  12. Area under the concentration-time curve (AUC) of picankibart

    Plasma concentration of picankibart is evaluated at each scheduled dosing timepoint. AUC represents the area under the concentration-time curve and gives insight into the extent of exposure to a drug and its clearance rate from the body.

    Time frame: From baseline to Week 56

  13. Percentage of participants who developed anti-drug antibody (ADA)

    ADAs are immune system-produced antibodies that specifically bind to therapeutic drugs, potentially altering their pharmacokinetics, efficacy, or safety.

    Time frame: From baseline to Week 56

  14. Percentage of participants who developed neutralizing antibody (NAb)

    NAbs are ADAs that inhibit the drug's biological function by blocking target interaction.

    Time frame: From baseline to Week 56

07

Study locations

1 of 1 sites recruiting
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
    Recruiting
    • Xiaoyong Man · Contactmanxy@zju.edu.cn · +86 57187783753
    • Xiaoyong Man, M.D. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2029, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 19, 2025
StartActual
Dec 18, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07295509
Responsible party
Sponsor
First posted
Dec 19, 2025
Start date
Dec 18, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Mar 20, 2026

Study contacts

Bingjing Feng
Contact
bingjing.feng@innoventbio.com
+86 18361923769

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Picankibart

Start the discussion